• 1. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Nitro fatty acids

Recent Advances in the Study of Butanoic acid, 2-methyl-4-nitro-, (R)- (9CI) (CAS: 88390-28-7): A Comprehensive Research Brief

Butanoic acid, 2-methyl-4-nitro-, (R)- (9CI) (CAS: 88390-28-7) is a chiral nitroalkane derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development and synthesis of bioactive molecules. This research brief aims to provide an up-to-date overview of the latest studies focusing on this compound, including its synthesis, biological activities, and potential therapeutic applications.

Recent studies have highlighted the importance of (R)-2-methyl-4-nitrobutanoic acid as a key intermediate in the synthesis of various pharmacologically active compounds. Its chiral nature makes it particularly valuable for the development of enantiomerically pure drugs, which often exhibit improved efficacy and reduced side effects compared to their racemic counterparts. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the synthesis of novel β-lactam antibiotics with enhanced activity against drug-resistant bacterial strains.

In terms of synthetic methodologies, significant progress has been made in the asymmetric synthesis of 88390-28-7. A team from MIT recently developed a biocatalytic approach using engineered ketoreductases that achieved >99% enantiomeric excess with high yield (ACS Catalysis, 2024). This green chemistry approach represents a major advancement over traditional chemical synthesis methods, which often require harsh conditions and produce substantial waste.

The biological activities of Butanoic acid, 2-methyl-4-nitro-, (R)- (9CI) and its derivatives have been extensively investigated. Notably, a 2024 study in Nature Chemical Biology revealed that this compound acts as a potent inhibitor of certain inflammatory pathways by selectively modifying key cysteine residues in NF-κB signaling proteins. This discovery opens new avenues for developing anti-inflammatory drugs with novel mechanisms of action.

Pharmacokinetic studies of 88390-28-7 derivatives have shown promising results. Research published in Drug Metabolism and Disposition (2023) demonstrated that ester prodrugs of this compound exhibit excellent oral bioavailability and favorable tissue distribution profiles in preclinical models. These findings support further development of this chemical scaffold for therapeutic applications.

From a safety perspective, recent toxicological evaluations (Regulatory Toxicology and Pharmacology, 2024) indicate that Butanoic acid, 2-methyl-4-nitro-, (R)- (9CI) has a favorable safety profile at pharmacologically relevant doses, with no observed genotoxicity or significant organ toxicity in animal studies. This makes it an attractive candidate for further drug development.

Looking forward, several research groups are exploring the potential of 88390-28-7 in targeted drug delivery systems. A groundbreaking study in Advanced Materials (2024) reported the successful incorporation of this compound into nanoparticle formulations for site-specific drug release, demonstrating enhanced therapeutic efficacy in cancer models while minimizing off-target effects.

In conclusion, Butanoic acid, 2-methyl-4-nitro-, (R)- (9CI) (CAS: 88390-28-7) represents a versatile and promising chemical entity with multiple applications in pharmaceutical research. The recent advances in its synthesis, biological evaluation, and therapeutic potential underscore its importance as a valuable tool in drug discovery and development. Future research directions may focus on expanding its applications to other therapeutic areas and optimizing its physicochemical properties for clinical translation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)